First Asian Regulatory Approvals Received for VivaGel® BV – Starpharma
15 August 2019 Melbourne, Australia: Starpharma today announced that it has received the first regulatory approvals in South East Asia for VivaGel® BV. Mundipharma will be rolling-out the product in Asia under the brand name BETADINETM BV Gel. BETADINETM BV Gel will…
Dr David Haylock joins VivaZome Therapeutics as Chief Scientific Officer
14 August 2019 Manufacturing development work begins at CSIRO VivaZome Therapeutics is pleased to announce that esteemed cell therapy scientist Dr David Haylock has joined the company as Chief Scientific Officer. Dr Haylock will lead the scientific and…
AdAlta Executive team changes
12 August 2019 The Board of AdAlta Limited (ASX:1AD), today announced that it has accepted the resignation of Ms Samantha Cobb as Chief Executive Officer and Managing Director. Over the last 12 years as founding CEO, Sam has…
Meta-Analysis Summary: Prolonged Cardiac Rhythm Monitoring and Secondary Stroke Prevention in Patients with Cryptogenic Cerebral Ischemia – Medtronic
12 August 2019 As published in Stroke, August 2019 You might be interested in a latest study published in Stroke (August). The study is the first outcome evidence available for long-term heart monitoring in patients with unexplained stroke.…
Medtronic Named On The 2019 AFR Boss Most Innovative Company List
9 August 2019 Sydney – Today, Medtronic Australasia Pty Ltd (Medtronic) was honoured to be recognised as one of Australia and New Zealand’s Most Innovative Companies. The prestigious annual list, published by The Australian Financial Review and Boss…
CSL to Move Global Headquarters to Parkville Biomedical Precinct
7 August 2019 Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination Victorian Minister for Priority Precincts media release – Final CSL_Jennings MR SP Melbourne:…
Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
7 August 2019 Company to Host Conference Call Today at 9:00 AM AEST 7:00PM EDT (Tuesday, August 6th U.S) -Dial-in details posted at end of release Primary outcome achieved: OPT-302 + Lucentis (ranibizumab) combination therapy demonstrated statistically significant…
Tiny blood cells could protect against cerebral palsy (WEHI)
2 August 2019 A Melbourne study supported by the Cerebral Palsy Alliance Research Foundation is following an exciting new lead that could help to protect newborn babies against cerebral palsy, the most common childhood disability in Australia. Platelets…
Frontiers Program Feedback for next Round
1 August 2019 The successful applicants for the first round of the Frontiers Program were announced in April this year, and attention has now turned to the next round which is anticipated to open in October. While the…
Exopharm requests trading halt ahead of capital raising for recently approved 20-patient phase 1 trial
23 July 2019 As reported in Biotech Daily Exopharm says it is ready for a 20-patient phase I trial of its Plexaris exosomo treatment for would healing, and has requesting a trading halt for a capital raising. Exopharm…
Smileyscope & Two Bulls Acknowledged for World-Class Digital Excellence in Winning the acclaimed Webby Award
23 July 2019 We were honoured and thrilled to have won the Webby Award with our amazing digital team Two Bulls. Webby Award, presented by The International Academy of Digital Arts and Sciences is described as “The Internet’s…
Smileyscope: Fundraising to Meet International Demand
23 July 2019 June and July have been very productive months for Smileyscope, as interest in our product continues to grow in both Australia and the USA. Following our highly successful clinical trial publication in The Journal of…
